Anbio Biotechnology Class A Ordinary Shares
NNNN
Rank in Stocks
#17161
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main,... Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Share Price
$3.82
Last synced: 2026-11-13
Market Cap
$167.66M
Change (1 day)
0.53%
Change (1 year)
-85.32%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Anbio Biotechnology Class A Ordinary Shares (NNNN)
Category
Healthcare
Operating Margin for Anbio Biotechnology Class A Ordinary Shares (NNNN)
Operating Margin as of November 2026 TTM: 65.20%
According to Anbio Biotechnology Class A Ordinary Shares's latest financial reports, its current operating margin (TTM) is 65.20%. At the end of 2025 the company had an operating margin of 66.70%.
Operating Margin history for Anbio Biotechnology Class A Ordinary Shares from 2021 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 65.20% | -2.25% |
| 2025 | 66.70% | 173.58% |
| 2024 | 24.38% | -16.56% |
| 2023 | 29.22% | -32.52% |
| 2022 | 43.30% | -21.93% |
| 2021 | 55.46% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 28.37% | -99.56% |
US
|
|
| 12.36% | -99.81% |
FR
|
|
| 9.83% | -99.85% |
US
|
|
| 31.11% | -99.52% |
JP
|
|
| 9.87% | -99.85% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Anbio Biotechnology Class A Ordinary Shares's operating margin
What is Anbio Biotechnology Class A Ordinary Shares's operating margin?
Anbio Biotechnology Class A Ordinary Shares's operating margin is 65.20%, as of Nov 2026.
What was Anbio Biotechnology Class A Ordinary Shares's operating margin in 2025?
In 2025, Anbio Biotechnology Class A Ordinary Shares's operating margin was 66.70%, compared with 24.38% in 2024.
How has Anbio Biotechnology Class A Ordinary Shares's operating margin changed since 2021?
From 2021 to 2025, Anbio Biotechnology Class A Ordinary Shares's operating margin was highest in 2025 (66.70%) and lowest in 2024 (24.38%).
How does Anbio Biotechnology Class A Ordinary Shares's operating margin compare with similar companies?
Anbio Biotechnology Class A Ordinary Shares's operating margin (65.20%) is higher than that of all 5 similar companies listed above. The highest among them is HOYA Corporation, with 31.11%.